Having been through the crash of ’87, ’98, ’01, ’08, and now, the feeling is similar.
Each time the vehicle (stock) is different but also the same, at the same time.
In case anyone wants to review, here’s the definition of ‘bag holder‘.
Is Now, The Time?
Previous analysis and potential top identification for NVDA, has been premature.
With that in mind, presented below are two charts.
One has the Fibonacci count from the October ’22 lows; the other, shows a trading channel overlay.
The inference is, we’re close to some kind of ‘event’ whether it be sideways congestion or reversal (not advice, not a recommendation).
Nvidia NVDA, Weekly
It appears, since the October ’22 lows, NVDA is being influenced by a Fibonacci sequence.
The ”close’ chart has the same Fibonacci count as well as the current trading channel.
Next week is ‘Week 88’, stock-split (10 to 1), as well as the Fed meeting.
Week 88, is within the margin of error for a precise Fibonacci count, Week 89.
With NVDA, at the top of its trading range, one needs to be on the lookout for some type of Fed/Stock-Split ‘overshoot’ or other indicator of potential upside limit (not advice, not a recommendation).
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
This time, instead of, The subprime crisis is contained”, we have, ‘The banking crisis is over’.
Back then, as the market crashed into ’09, and then forced (manipulated) higher into 2010 and later, you intuitively knew the next time, there’s no saving it (not advice, not a recommendation).
So, here we are … at the ‘next time’.
However, this time around, it’s different … very different.
Coming out nearly every day, is the massive driver to the downside: Biotech. The updated list on that sector is provided at the end of this post.
For this update, we’re looking at the technical condition and more specifically, biotech leveraged inverse fund LABD.
Biotech Leveraged Inverse LABD, Daily
We’re early in the session (11:03, a.m., EST) and we can see a reversal (if it holds) developing.
Today, is also Fibonacci Day 5, from the high set last Friday, the 24th.
Since today may be a pivot to the upside (biotech index lower), a potential continuation channel line is drawn in the chart below.
As mentioned in the last update, a retrace was probable and hence taking profits with a partial exit.
During the past four trading days, that position has been re-established at lower prices (not advice, not a recommendation).
Insurmountable Fundamentals.
At some point unknown to us, the fundamentals will come into play.
The conditions are insurmountable … they can’t be ignored.
Said many times, this is the driving factor for the market(s) on a go-forward basis (not advice, not a recommendation).
Latest on The Biotech List
We’re going to start first with an article that surmises, the blow-up has already happened. That article is here. The report starts off with profanity; be advised.
Then, the biotech list; growing without bound:
Risk Of Cardiac Death Tripled For Young Women Following AstraZeneca COVID-19 Vaccination: Study
Bombshell Vax Analysis Finds $147 Billion In Economic Damage, Tens Of Millions Injured Or Disabled
CDC Found COVID-19 Vaccine Safety Signals Months Earlier Than Previously Known, Files Show
Three Years To Slow The Spread: COVID Hysteria & The Creation Of A Never-Ending Crisis
Biden Signs Bill To Declassify COVID Origins Intel
“I Couldn’t Remain Silent”: Physician Assistant Fired For Reporting COVID-19 Vaccine Adverse Events To VAERS
A Haunting Anniversary – ’15 Days To Slow The Spread’
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
It’s going to be a very different place come December.
This won’t be like ’08 -’09, where all the stops are being pulled to ‘rescue’ the market.
No, this time really is different.
We can all see by now; the plan is controlled demolition.
Paraphrasing Jerimiah Babe, and Pinball Preparedness, we haven’t even got started (with the collapse) and the public’s already folding up.
What’s it going to be like when it really hits?
This past week, all the major indices have gone through some type of relief rally. Call it a Santa Claus rally because there probably won’t be one this December.
Trading Consistency
Throughout this upward correction, the case has been made over and again, only biotech SPBIO’s in a technical (and fundamental) condition that would allow it to decline farthest and fastest (not advice, not a recommendation).
Wyckoff analysis along with Livermore’s strategic approach that’s coupled with Loeb’s ‘focus’, has led us to (shorting) this sector exclusively.
Strategy, Tactics, Focus
Biotech SPBIO, Weekly Close
Looking at the far-right side of the chart, SPBIO rallied this past week. It looks like it may head higher … that is, until we put in the trend-lines.
Now, let’s put in the trendlines.
Extended trendlines show the downside potential.
We’re about to see how this works out.
Friday’s upward action in SPBIO slowed with inverse LABD, posting narrow (downside) action as well.
Ready to reverse.
Summary
Trading action in the past week amounted to reducing the position size in LABD-22-05, by about 4.6% (not advice, not a recommendation).
If and when SPBIO continues is downward trajectory, that position (shorting via LABD) will again be increased as the market allows.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.